医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

WuXi AppTec Expands Investment in Instem Software Solutions

2015年06月03日 PM09:01
このエントリーをはてなブックマークに追加


 

CONSHOHOCKEN, Pa.

Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that WuXi AppTec (WuXi) has committed to a further, major investment in Instem solutions to support its ongoing growth plans.

WuXi is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with operations in China and the United States. In 2009, WuXi selected Instem’s integrated Provantis preclinical solution suite to automate study processes at its newly constructed 314,000 square feet toxicology facility in Suzhou. WuXi invested in Provantis to support its ongoing commitment to helping worldwide customers shorten drug discovery and development time and lower the cost of drug and medical device R&D.

This latest contract from WuXi includes a comprehensive set of services to facilitate WuXi’s upgrade to Provantis 9, the addition of the Provantis Reproductive Toxicology module and a 50% increase in user licenses.

Importantly the contract also includes the purchase of the Ames Study Manager (ASM) software from Perceptive Instruments (now part of Instem), which has recently been launched in the China market. WuXi has also purchased the Sorcerer Colony Counter and associated implementation services.

Key Facts

  • WuXi to implement the Provantis Reproductive Toxicology module to support the management, performance, analysis and reporting of all reproductive study types
  • WuXi to implement the Ames Study Manager (ASM) software, an integrated suite of software for conducting the Bacterial Reverse Mutation Test, together with a Sorcerer Colony Counter and associated implementation services
  • WuXi to upgrade to Provantis 9, the latest version of Instem’s world-leading preclinical software solution, adding further user licenses
  • Comprehensive package of services purchased to facilitate quick implementation and a rapid return on investment

Dr. Yi Jin, Vice President of Toxicology, WuXi said “The deployment of Instem solutions at our Suzhou facility has been instrumental in helping us to achieve our ambitious growth plans and has enabled us to deliver even higher levels of customer service to our global client base. We look forward to further strengthening our partnership with Instem through our expanded investment in Instem solutions.”

Mr. Neil Donaldson, VP Sales Europe & Asia, Instem, commented “Our partnership with WuXi has successfully developed over the years and we are delighted that they have chosen to increase and expand the use of Instem solutions across their facility.”

About WuXi AppTec

Established in December 2000, WuXi AppTec (NYSE: WX) is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with operations in China and the United States. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. WuXi AppTec’s services are designed to help its worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.

WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 9,000 employees and 5 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services both in China and in the United States, WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.

To learn more about WuXi AppTec please visit https://www.wuxiapptec.com/

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com

Meeting clients at the intersection of investment & return™.

http://www.linkedin.com/company/instem/

https://www.facebook.com/Instem.software

https://twitter.com/Instemsoftware

View source version on businesswire.com: http://www.businesswire.com/news/home/20150603005796/en/

CONTACT

Instem
Gary Mitchell (US HQ)
610-941-0990
gary.mitchell@instem.com
or
Julie
Jones (UK HQ)
+44 (0) 1785 825600
julie.jones@instem.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持